
Jared Barsky
Examiner (ID: 7259, Phone: (571)272-2795 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1628 |
| Total Applications | 1117 |
| Issued Applications | 492 |
| Pending Applications | 146 |
| Abandoned Applications | 503 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19541683
[patent_doc_number] => 20240358719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation
[patent_app_type] => utility
[patent_app_number] => 18/553474
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10135
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -82
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553474
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553474 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | Mar 30, 2021 | Pending |
Array
(
[id] => 18449464
[patent_doc_number] => 20230190740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS)
[patent_app_type] => utility
[patent_app_number] => 17/907291
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9370
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907291
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907291 | AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) | Mar 29, 2021 | Pending |
Array
(
[id] => 16961468
[patent_doc_number] => 20210212967
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => Treatment of Irritable Bowel Syndrome
[patent_app_type] => utility
[patent_app_number] => 17/215050
[patent_app_country] => US
[patent_app_date] => 2021-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215050
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/215050 | Treatment of Irritable Bowel Syndrome | Mar 28, 2021 | Abandoned |
Array
(
[id] => 18842674
[patent_doc_number] => 20230405078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => DETECTION AND TREATMENT OF INTESTINAL FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 17/907220
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27163
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907220
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907220 | DETECTION AND TREATMENT OF INTESTINAL FIBROSIS | Mar 25, 2021 | Abandoned |
Array
(
[id] => 18326014
[patent_doc_number] => 20230124142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT
[patent_app_type] => utility
[patent_app_number] => 17/907305
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907305
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907305 | NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT | Mar 25, 2021 | Abandoned |
Array
(
[id] => 20818515
[patent_doc_number] => 12673976
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-07-07
[patent_title] => Preparation of cyclosporin derivatives
[patent_app_type] => utility
[patent_app_number] => 17/906348
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2178
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906348 | Preparation of cyclosporin derivatives | Mar 24, 2021 | Issued |
Array
(
[id] => 18339980
[patent_doc_number] => 20230131929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/914146
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914146
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/914146 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | Mar 23, 2021 | Pending |
Array
(
[id] => 18575492
[patent_doc_number] => 11732006
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-22
[patent_title] => IBAT inhibitors for the treatment of liver diseases
[patent_app_type] => utility
[patent_app_number] => 17/206925
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14314
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206925
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/206925 | IBAT inhibitors for the treatment of liver diseases | Mar 18, 2021 | Issued |
Array
(
[id] => 18312376
[patent_doc_number] => 20230116276
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS
[patent_app_type] => utility
[patent_app_number] => 17/906186
[patent_app_country] => US
[patent_app_date] => 2021-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906186 | Dietary supplement comprising aldehyde functional monoterpenoids | Mar 15, 2021 | Issued |
Array
(
[id] => 18346733
[patent_doc_number] => 20230134843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => TREATMENT OF STEM CELL DEFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/910971
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910971
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/910971 | TREATMENT OF STEM CELL DEFICIENCY | Mar 10, 2021 | Pending |
Array
(
[id] => 18418419
[patent_doc_number] => 20230172877
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS
[patent_app_type] => utility
[patent_app_number] => 17/910613
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23299
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910613
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/910613 | METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS | Mar 10, 2021 | Pending |
Array
(
[id] => 18700038
[patent_doc_number] => 11786524
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Pharmaceutical compounds
[patent_app_type] => utility
[patent_app_number] => 17/191151
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50030
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1045
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191151
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/191151 | Pharmaceutical compounds | Mar 2, 2021 | Issued |
Array
(
[id] => 16898918
[patent_doc_number] => 20210177834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
[patent_app_type] => utility
[patent_app_number] => 17/187454
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33318
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187454
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187454 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Feb 25, 2021 | Abandoned |
Array
(
[id] => 18279073
[patent_doc_number] => 20230094545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => S1P RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/799904
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17225
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17799904
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/799904 | S1P RECEPTOR MODULATORS | Feb 25, 2021 | Pending |
Array
(
[id] => 16898871
[patent_doc_number] => 20210177787
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => INHALATION FORMULATIONS OF TREPROSTINIL
[patent_app_type] => utility
[patent_app_number] => 17/185370
[patent_app_country] => US
[patent_app_date] => 2021-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14621
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17185370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/185370 | INHALATION FORMULATIONS OF TREPROSTINIL | Feb 24, 2021 | Abandoned |
Array
(
[id] => 16930815
[patent_doc_number] => 20210196704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
[patent_app_type] => utility
[patent_app_number] => 17/183645
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 154
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17183645
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/183645 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Feb 23, 2021 | Abandoned |
Array
(
[id] => 17005287
[patent_doc_number] => 20210236448
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => METABOLISM-IMPROVING AGENT COMPRISING RARE FATTY ACID
[patent_app_type] => utility
[patent_app_number] => 17/175186
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175186
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175186 | Metabolism-improving agent comprising rare fatty acid | Feb 11, 2021 | Issued |
Array
(
[id] => 20115008
[patent_doc_number] => 12364692
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Topical naloxone compositions and methods for using the same
[patent_app_type] => utility
[patent_app_number] => 17/791134
[patent_app_country] => US
[patent_app_date] => 2021-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 15
[patent_no_of_words] => 12165
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791134
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/791134 | Topical naloxone compositions and methods for using the same | Feb 10, 2021 | Issued |
Array
(
[id] => 17005338
[patent_doc_number] => 20210236499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => IMIPRIDONES FOR GLIOMAS
[patent_app_type] => utility
[patent_app_number] => 17/171532
[patent_app_country] => US
[patent_app_date] => 2021-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171532
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/171532 | Imipridones for gliomas | Feb 8, 2021 | Issued |
Array
(
[id] => 16939873
[patent_doc_number] => 11052088
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Kinase inhibitor salts, and compositions thereof
[patent_app_type] => utility
[patent_app_number] => 17/167719
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 29
[patent_no_of_words] => 51818
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167719
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167719 | Kinase inhibitor salts, and compositions thereof | Feb 3, 2021 | Issued |